New! Sign up for our free email newsletter.
Science News
from research organizations

First trimester exposure to antithyroid drugs associated with birth defects

Date:
January 22, 2018
Source:
American College of Physicians
Summary:
Taking antithyroid drugs (ATDs) during the first trimester of pregnancy is associated with an increased risk for birth defects, particularly for women receiving prescriptions for methimazole (MMI) or both MMI and propylthiouracil (PTU).
Share:
FULL STORY

Taking antithyroid drugs (ATDs) during the first trimester of pregnancy is associated with an increased risk for birth defects, particularly for women receiving prescriptions for methimazole (MMI) or both MMI and propylthiouracil (PTU). The findings are published in Annals of Internal Medicine.

Researchers from Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Korea, conducted a nationwide cohort study to examine the association between maternal prescriptions for ATDs and congenital malformations in live births. The study included a cohort of 2,886,970 pregnancies linked to live-born infants in 2,210,253 women between 2008 and 2010. Of those, 12,891 pregnancies were exposed to ATDs during the first trimester. The data showed that prenatal exposure to MMI and PTU during the first trimester resulted in relative increases in the risk for congenital malformations of 31% and 16%, respectively. The increased risk for malformations associated with MMI remained among those who switched to PTU several months before their pregnancy or during the first trimester.

The researchers conclude that ATD exposure during the first trimester of pregnancy is associated with significantly increased risk for congenital malformations. These findings confirm the importance of minimizing MMI use in the first trimester and suggest that the current recommendation of switching from MMI to PTU after pregnancy detection should be reconsidered.


Story Source:

Materials provided by American College of Physicians. Note: Content may be edited for style and length.


Journal Reference:

  1. Gi Hyeon Seo, Tae Hyuk Kim, Jae Hoon Chung. Antithyroid Drugs and Congenital Malformations. Annals of Internal Medicine, 2018; DOI: 10.7326/M17-1398

Cite This Page:

American College of Physicians. "First trimester exposure to antithyroid drugs associated with birth defects." ScienceDaily. ScienceDaily, 22 January 2018. <www.sciencedaily.com/releases/2018/01/180122184720.htm>.
American College of Physicians. (2018, January 22). First trimester exposure to antithyroid drugs associated with birth defects. ScienceDaily. Retrieved April 23, 2024 from www.sciencedaily.com/releases/2018/01/180122184720.htm
American College of Physicians. "First trimester exposure to antithyroid drugs associated with birth defects." ScienceDaily. www.sciencedaily.com/releases/2018/01/180122184720.htm (accessed April 23, 2024).

Explore More

from ScienceDaily

RELATED STORIES